Michael Faerm

Chief Financial Officer

Michael E. Faerm has served as our Chief Financial Officer since April 2021. From May 2019 to April 2021, Mr. Faerm served as a consulting and interim Chief Financial Officer and Chief Business Officer to biopharmaceutical companies through his firm, MEF Consulting LLC, and through Burkland Associates. From July 2015 to February 2018, Mr. Faerm was the Chief Business Officer at Innoviva, Inc., a publicly-traded biopharmaceutical company. Prior to joining Innoviva, Mr. Faerm was a pharmaceuticals equity research analyst, in positions including the Senior Pharmaceuticals Analyst at Wells Fargo Securities, from June 2013 to June 2015, and Senior Specialty Pharmaceuticals Analyst and Major Pharmaceuticals Associate Analyst at Credit Suisse from January 2006 to March 2013. Mr. Faerm has also worked within the biopharmaceutical industry, holding positions in business development and strategic financial planning at Forest Laboratories and Regeneron Pharmaceuticals. Previously, he was an investment banker as a member of Merrill Lynch’s global healthcare team, where he focused primarily on mergers and acquisitions and financings for biotechnology and pharmaceuticals companies. Mr. Faerm received his MBA from Harvard Business School, his M.S. in civil engineering from Stanford University and his B.S. in civil engineering from Columbia University.